HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $70 Price Target

Benzinga · 09/03/2025 10:51
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Buy and maintains $70 price target.